![]() |
|
|
Vol. 286, Issue 2, 697-703, August 1998
Departments of Psychology and Pharmacology, University of Michigan
Medical School, Ann Arbor, Michigan
This study characterized the antinociceptive, respiratory and heart
rate effects of the cannabinoid receptor agonists
-9-tetrahydrocannabinol (
-9-THC) and WIN 55212 {(R)-(+)-2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrol-[1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphtalenyl)methanone monomethanesulfonate}, N-arachidonyl ethanolamide (anandamide) and the mu and kappa opioid receptor
agonists heroin and U69593, alone and in conjunction with a cannabinoid
receptor antagonist, SR 141716A
[N-(piperidin-1-1-yl)-5-(4-chlorophenyl)-1(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride] and an opioid receptor antagonist, quadazocine, in
rhesus monkeys (Macaca mulatta). Using 12 adult rhesus
monkeys, latencies to remove the tail from a 50°C water bath,
respiration in 5% CO2 and heart rate were measured. When
administered alone, SR 141716A (1.8, 5.6 mg/kg i.m.) did not alter
nociception, respiration or heart rate.
-9-THC (0.1-10 mg/kg i.m.)
and WIN 55212 (0.1-10 mg/kg i.m.) dose-dependently increased
antinociception and dose-dependently decreased respiratory minute and
tidal volumes and heart rate. These antinociceptive, respiratory and
heart rate effects were reversed by SR 141716A but not by the opioid
antagonist quadazocine (1 mg/kg i.m.). Anandamide (10 mg/kg i.m.) also
produced antinociception. Heroin (0.01-10 mg/kg i.m.) and U69593
(0.01-3.2 mg/kg i.m.) also dose-dependently increased antinociception
and decreased respiratory and heart rate measures; these effects were
antagonized by quadazocine but not by SR 141716A. These results
demonstrate selective and reversible antagonism of cannabinoid
behavioral effects by SR 141716A in rhesus monkeys.